LIPOPROTEIN LEVELS FOLLOWING TREATMENT WITH CYPROTERONE-ACETATE OR LHRH ANALOGS

Fasting serum lipoproteins were measured in patients with carcinoma of the prostate. Twelve patients were on no hormonal treatment (Group 1) . Fifteen were on cyproterone acetate (Group 3), 17 were on the long-a cting LH RH analogue Zoladex (Group 4) and 11 on a combination of cypr oterone acetate and Zoladex (group 5). ln addition, 27 patients with b enign urological disease were taken as controls (Group 2). In both gro ups in which cyproterone acetate was part of the treatment the total h igh density lipoprotein cholesterol levels were significantly lower th an in the other groups. Patients on cyproterone acetate alone had sign ificantly higher levels of very low density lipoprotein (VLDL) triglyc eride levels than those not on cyproterone acetate. These results conf irm changes in serum lipoprotein levels in patients taking cyproterone acetate and these changes may have potential adverse effects if the t reatment is prolonged.